阿尔茨海默病中的TREM2和sTREM2:从机制到疗法
Lianshuai Zhang1,2, Xianyuan Xiang3,4, Yahui Li1,2
1State Key Laboratory of Cellular Stress Biology, Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, Fujian, 361102, China.
触发受体表达在骨髓细胞2 (TREM2) 在神经退行过程中至关重要,调节微质反应. 可溶性TREM2 (sTREM2) 是阿尔茨海默病 (AD) 的生物标志物和治疗点.
科学领域:
- 神经免疫学 神经免疫学
- 分子生物学分子生物学
- 神经退行性疾病 神经退行性疾病
背景情况:
- 在骨髓细胞2表达的触发受体 (TREM2) 是大脑微质上的一种先天免疫受体.
- 在神经退行过程中,TREM2充当信号中心,应对病理变化和组织损伤.
- TREM2通过多种带结合来调节微质细胞化,炎症和新陈代谢.
研究的目的:
- 在阿尔茨海默病 (AD) 中提供TREM2和可溶性TREM2 (sTREM2) 的全面概述.
- 探索TREM2和sTREM2在AD中的诊断和治疗潜力.
- 确定基于TREM2/sTREM2的AD策略的关键研究方向.
主要方法:
- 对TREM2和sTREM2的现有临床和临床前证据的审查.
- 分析分子功能,调节机制和病理作用.
- 探索生物标志物和治疗标潜力.
主要成果:
- TREM2存在于膜结合和可溶性 (sTREM2) 形式,可以在生物流体中检测到.
- sTREM2是通过脱落或替代拼接生成的.
- 新出现的证据支持TREM2和sTREM2作为AD的诊断生物标志物和治疗点.
结论:
- 在与神经退行相关的微质免疫反应中,TREM2起着核心作用.
- TREM2和sTREM2对阿尔茨海默病的诊断和治疗具有重大潜力.
- 需要进一步的研究来推进基于TREM2/sTREM2的策略来对抗AD.
更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
相关概念视频
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Parkinson's Disease: Overview
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
